Tarsadia Investments
Tarsadia Investments describes a permanent-capital, multi-strategy family office platform with mandates covering direct investments, life sciences, real estate, strategic opportunities, and global markets.
What stands out about Tarsadia Investments
Tarsadia Investments publicly describes a multi-strategy family office platform using permanent capital across private equity, venture, real assets, and global markets. Its disclosed areas include technology, life sciences, hospitality and other real estate, strategic situations, fintech and payments, and public-market investments. Owners should clarify the applicable strategy and legal entity, proposed ownership and governance terms, investment horizon, follow-on capacity, and transaction structure.[1][2][3][6][8]
What does Tarsadia Investments invest in?
Tarsadia Investments describes itself as a generational family office investment platform and multi-strategy investor spanning private equity, venture, real assets, and global markets.
The platform publicly lists five investment mandates: Alpha-T Direct, Life Sciences, Real Estate, Strategic Opportunities, and Tarsadia Capital. Its stated activities include private investing, technology transformation, life-sciences investing, hospitality acquisitions and development, and global-market investing.[1]
Tarsadia states that it uses permanent capital, a generational horizon, operator-level diligence, and an owner’s time horizon when evaluating investments. The firm also describes its capital as patient while emphasizing decisive deployment.
Its fintech commentary says the firm prioritizes innovative founders navigating secular industry shifts and seeks ventures with unique models, cutting-edge technology, or distinct strategies.[1][8]
Owners comparing capital alternatives can review Auxo’s capital advisory services, valuation services, and full-versus-partial sale framework.
What should a business owner evaluate before taking capital from Tarsadia Investments?
Owners evaluating Tarsadia should identify which strategy and legal entity would invest, because the platform publicly describes several distinct mandates and SEC filings identify investment-manager relationships involving separate entities and private investment vehicles.
Owners should clarify the proposed ownership position, valuation methodology, governance and consent rights, expected investment horizon, follow-on capital, operating resources, transition expectations, and liquidity or exit expectations. The official homepage does not provide universal size parameters or a numeric holding-period range, and the cited portfolio-news pages do not disclose complete terms for the highlighted examples.
Owners should also verify the regulatory status applicable to the investing entity and the specific transaction.[1][6][7]
What ownership percentage, check size, valuation methodology, and investment horizon would apply to the proposed transaction
Would the proposed structure include board representation, consent rights, rollover equity, seller employment or transition commitments, or exclusivity
What investment criteria does Tarsadia Investments publicly describe?
Publicly identified focus areas include technology transformation and venture/growth investing; drug delivery, biosimilars, and clinical-stage therapeutics; hospitality and other real estate; private-market special situations; fintech and software; payments; healthcare technology; global equities; commodities; and select private co-investments.
The Real Estate team states that it oversees hotel, office, and net-lease assets across the country and grows the portfolio through strategic partnerships with sponsors focused on primary markets.[1][9]
Tarsadia’s public materials emphasize operator-level diligence and an owner’s time horizon. In its fintech commentary, the firm says it prioritizes innovative founders navigating secular industry shifts and seeks ventures with unique models, cutting-edge technology, or distinct strategies.
The official homepage does not state a universal minimum investment size, maximum investment size, or transaction-size range.[1][8]
Tarsadia lists offices at 520 Newport Center Drive in Newport Beach, California, and 712 Fifth Avenue in New York, New York. Tarsadia Capital describes investing across global equities and commodities.
The Real Estate team describes hotel, office, and net-lease assets across the country. Separately, a Tarsadia portfolio-news page reports that Kashiv BioSciences entered into an exclusive licensing agreement with Alvotech involving commercialization territories in the European Union, the United Kingdom, Australia, Canada, and New Zealand.[1][2][9]
Official portfolio and news materials identify Pagos as a Tarsadia portfolio company in payment data intelligence and payment optimization software. They also describe Petal’s launch of Prism Data, a separate company offering cash-flow-based underwriting technology to financial providers.
In life sciences, Tarsadia’s portfolio-news pages report Kashiv BioSciences’ exclusive licensing agreement with Alvotech for development and commercialization of ADL018, also called AVT23, in specified territories, and Kashiv’s collaboration with Amneal Pharmaceuticals in connection with FDA approval of RELEUKO, a filgrastim biosimilar.
An SEC Schedule 13D/A identifies Tarsadia Investments, LLC as an investment manager to NVGA I, LLC and CP (HLTH), LLC in connection with reported Cue Health securities ownership.[2][3][4][5][6]
Publicly identifiable activity includes SEC Schedule 13D/A disclosures involving Tarsadia Investments, LLC as an investment manager in connection with reported Cue Health securities ownership.
Official portfolio-news materials report Kashiv BioSciences’ exclusive licensing agreement with Alvotech concerning ADL018/AVT23 and its collaboration with Amneal Pharmaceuticals in connection with RELEUKO’s FDA approval.[2][3][6]
What is not clear from Tarsadia Investments's public materials?
The official homepage does not state a universal minimum investment size, maximum investment size, or transaction-size range. That page also states the firm’s permanent-capital and generational-horizon approach but does not publish a numeric expected investment holding-period range or universal exit timetable.
The official Kashiv-Alvotech portfolio-news page does not disclose the transaction’s upfront payment amount, milestone-payment amounts, royalty rates, valuation, or ownership percentage. The official Kashiv-RELEUKO portfolio-news page does not disclose the collaboration’s financial terms, ownership percentage, valuation, or consideration structure.
The SEC Schedule 13D/A reports securities ownership and investment-manager relationships but does not establish a comprehensive firm-level investment-adviser or broker-dealer registration status for Tarsadia Investments, LLC.[1][2][3][6]
Questions to ask before taking capital from Tarsadia Investments
Which Tarsadia strategy and legal entity would evaluate and make the investment?
What ownership percentage, check size, valuation methodology, and investment horizon would apply to the proposed transaction?
Would the proposed structure include board representation, consent rights, rollover equity, seller employment or transition commitments, or exclusivity?
What follow-on capital and operating resources would be available for the company?
Which comparable investments remain current holdings, and what liquidity or exit expectations apply?
What regulatory status applies to the investing entity and the specific transaction?
Sources & research notes
- Official website / firm overview
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- SEC filing / regulatory record
- SEC filing / regulatory record
- Investment approach
- Property / asset focus
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.